Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -54.27%-2.42M | 72.81%-179.29K | 29.72%-411.99K | -529.11%-680.78K | -436.29%-1.15M | -53.13%-1.57M | -164.33%-659.42K | -27.97%-586.19K | -8.85%-108.21K | 1.37%-213.73K |
Net income from continuing operations | 19.18%-2.73M | 58.71%-486.07K | 70.15%-471.26K | -102.44%-805.41K | -337.83%-964.05K | -167.41%-3.37M | -536.46%-1.18M | -489.79%-1.58M | -6.06%-397.85K | 75.22%-220.19K |
Operating gains losses | ---- | ---- | ---- | ---- | ---- | 127.60%119.83K | --0 | --0 | --165.54K | -113.58%-45.71K |
Depreciation and amortization | 24,459.43%223.98K | 6,199.88%50.71K | 47,192.52%50.6K | --49.68K | --72.99K | --912 | --805 | --107 | --0 | --0 |
Other non cash items | ---225.5K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Change In working capital | -135.81%-71.63K | -10.84%415.49K | 60.83%-93.69K | -248.86%-30.11K | -673.11%-363.32K | 40.58%200.05K | 575.32%466.02K | -239.26%-239.2K | -69.78%20.23K | -161.13%-46.99K |
-Change in receivables | -215.13%-150.79K | 90.89%79.35K | -620.53%-205.11K | -41.70%9.6K | 55.26%-34.64K | -166.14%-47.85K | 3.79%41.57K | 46.74%-28.47K | 3,842.50%16.47K | -189.84%-77.42K |
-Change in prepaid assets | 122.10%25.69K | -197.61%-66.01K | 117.88%32.88K | --60.54K | ---1.72K | -2,147.06%-116.22K | 1,338.26%67.63K | ---183.85K | --0 | --0 |
-Change in payables and accrued expense | -152.53%-199.5K | -49.84%187.31K | -29.09%-34.71K | -1,002.12%-25.13K | -1,174.51%-326.96K | 376.99%379.76K | 1,439.85%373.43K | -57.62%-26.89K | -95.56%2.79K | 216.31%30.43K |
-Change in other current assets | 79.17%-2.34K | 102.63%295 | --74.89K | ---- | ---- | -150.50%-11.23K | ---11.23K | --0 | ---- | ---- |
-Change in other current liabilities | -400.52%-2.91K | -96,900.00%-968 | -200.41%-972 | ---- | ---- | --969 | --1 | --968 | ---- | ---- |
-Change in other working capital | 4,900.63%258.23K | --215.51K | --39.33K | --3.38K | --5 | ---5.38K | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -54.27%-2.42M | 72.81%-179.29K | 29.72%-411.99K | -529.11%-680.78K | -436.29%-1.15M | -53.13%-1.57M | -164.33%-659.42K | -27.97%-586.19K | -8.85%-108.21K | 1.37%-213.73K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 74.95%-22.31K | 91.71%-6.63K | 72.45%-2.5K | -6.8K | -6.38K | -89.05K | -79.98K | -9.07K | 0 | 0 |
Net PPE purchase and sale | 31.81%-19.81K | 66.80%-6.63K | --0 | ---6.8K | ---6.38K | ---29.05K | ---19.98K | ---9.07K | --0 | --0 |
Net intangibles purchase and sale | ---2.5K | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | ---60K | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 74.95%-22.31K | 91.71%-6.63K | 72.45%-2.5K | ---6.8K | ---6.38K | ---89.05K | ---79.98K | ---9.07K | --0 | --0 |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -102.04%-117.54K | -12,900.00%-65K | -101.11%-53.77K | 0 | 1.23K | 1,832.99%5.75M | 98.92%-500 | 1,873.08%4.83M | 1,801.13%922.37K | 0 |
Net common stock issuance | -100.09%-5.24K | --0 | ---- | ---- | ---- | 3,303.78%5.65M | -7.76%-500 | ---- | ---- | ---- |
Net preferred stock issuance | --0 | --0 | --0 | ---- | ---- | --1M | --0 | --0 | ---- | ---- |
Proceeds from stock option exercised by employees | --1.23K | --0 | --0 | --0 | --1.23K | --0 | --0 | --0 | --0 | --0 |
Net other financing activities | 87.37%-113.53K | -13,100.00%-65K | ---- | ---- | ---- | -481.93%-898.91K | 101.09%500 | -1,892.46%-821.77K | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -102.04%-117.54K | ---65K | -101.11%-53.77K | --0 | --1.23K | 1,832.99%5.75M | --0 | 1,872.87%4.83M | 1,801.13%922.37K | --0 |
Net cash flow | ||||||||||
Beginning cash position | 417.33%5.08M | -52.39%2.77M | 104.65%3.24M | 411.37%3.92M | 417.33%5.08M | -42.53%981.13K | 355.34%5.82M | 6.12%1.58M | -53.32%767.39K | -42.53%981.13K |
Current changes in cash | -162.48%-2.56M | 66.06%-250.92K | -111.06%-468.26K | -184.45%-687.58K | -438.69%-1.15M | 663.87%4.09M | -149.85%-739.4K | 2,084.59%4.23M | 629.91%814.15K | -237.93%-213.73K |
End cash Position | -50.40%2.52M | -50.40%2.52M | -52.39%2.77M | 104.65%3.24M | 411.37%3.92M | 417.33%5.08M | 417.33%5.08M | 355.34%5.82M | 6.12%1.58M | -53.32%767.39K |
Free cash flow | -52.86%-2.44M | 72.63%-185.92K | 30.37%-414.49K | -535.39%-687.58K | -439.27%-1.15M | -55.97%-1.6M | -172.34%-679.4K | -29.95%-595.27K | -8.85%-108.21K | 1.37%-213.73K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |